ADMA Biologics, Inc.
ADMA
$16.15
-$0.44-2.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 510.17M | 488.56M | 474.17M | 459.38M | 426.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 510.17M | 488.56M | 474.17M | 459.38M | 426.45M |
| Cost of Revenue | 217.41M | 221.28M | 222.86M | 217.84M | 206.90M |
| Gross Profit | 292.77M | 267.28M | 251.32M | 241.54M | 219.55M |
| SG&A Expenses | 96.42M | 96.37M | 92.91M | 87.09M | 78.37M |
| Depreciation & Amortization | 146.00K | 120.00K | 110.00K | 220.00K | 388.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 318.73M | 321.55M | 318.53M | 307.34M | 287.47M |
| Operating Income | 191.44M | 167.01M | 155.64M | 152.04M | 138.98M |
| Income Before Tax | 182.66M | 155.78M | 145.01M | 140.76M | 125.71M |
| Income Tax Expenses | 35.73M | -53.67M | -63.92M | -66.01M | -71.96M |
| Earnings from Continuing Operations | 146.93 | 209.45 | 208.93 | 206.77 | 197.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.93M | 209.45M | 208.93M | 206.77M | 197.67M |
| EBIT | 191.44M | 167.01M | 155.64M | 152.04M | 138.98M |
| EBITDA | 199.54M | 175.01M | 163.55M | 159.94M | 147.03M |
| EPS Basic | 0.62 | 0.88 | 0.88 | 0.88 | 0.84 |
| Normalized Basic EPS | 0.49 | 0.42 | 0.39 | 0.38 | 0.34 |
| EPS Diluted | 0.60 | 0.82 | 0.82 | 0.81 | 0.78 |
| Normalized Diluted EPS | 0.47 | 0.41 | 0.37 | 0.36 | 0.33 |
| Average Basic Shares Outstanding | 955.84M | 954.30M | 950.27M | 941.20M | 932.30M |
| Average Diluted Shares Outstanding | 981.80M | 983.85M | 983.99M | 977.55M | 969.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |